cCAM Biotherapeutics Receives Phase I FDA Approval – NoCamels

//cCAM Biotherapeutics Receives Phase I FDA Approval – NoCamels

cCAM Biotherapeutics Receives Phase I FDA Approval – NoCamels

By | 2015-01-07T15:14:36+00:00 January 7th, 2015|Health|0 Comments

cCAM Biotherapeutics Receives Phase I FDA Approval

ccamlogoJanuary 7, 2015 | An Israeli biopharmaceutical company, cCAM Biotherapeutics, announced that it received Food Drug Administration approval to begin a Phase I trial for CM-24. CM-24 is a antibody for the treatment of various types of cancers. cCAM was founded in 2010 and focuses on the discovery and development of novel immunotherapies to treat cancer. The CM-24 antibody was discovered by Dr. Gal Markel, Head of Research in the Ella Institute of Melanoma at Sheba Academic Medical Center.